Table VI.
Final Model with for Black Participants in SARP (n=267)
| Variable | OR | 95%CI | p>|z| |
|---|---|---|---|
| Age | 1.06 | 1.02–1.09 | 0.002 |
| Center | 0.93 | 0.81–1.07 | 0.318 |
| Employed | 0.72 | 0.35–1.48 | 0.366 |
| 1 Family history | 1.50 | 0.62–3.60 | 0.367 |
| 2+ Family history | 2.79 | 1.13–6.87 | 0.026 |
| GERD | 3.59 | 1.62–7.97 | 0.002 |
| Baseline FEV1% pred | 0.96 | 0.94–0.98 | <.0001 |
| Max FEV1 Reversal | 0.98 | 0.96–1.00 | 0.058 |
| IgE | 2.12 | 1.16–3.87 | 0.014 |
| ≥5 positive skin tests | 0.46 | 0.21–1.01 | 0.053 |
*
Age=Age when enrolled into SARP, Age Onset=Age when first diagnosed with asthma, Center= clinical center site, 1 Family History= Have 1 family member with asthma, 2+ Family History= Have 2 or more family members with asthma, GERD=gastroesophogeal reflux disease, FEV1=forced expiratory volume in one second, IgE=Immunoglobulin E
*
IgE entered as continuous log-transformed variable in the model
*
Adjusted for current age (age of SARP enrollment) & clinical center